Par Pharma wins on invalidity in Ultram ER patent case
This article was originally published in Scrip
Executive Summary
A US district court has ruled in Par Pharmaceutical's favour on invalidity in its challenge of Purdue Pharma's patents relating to once-daily Ultram ER (extended-release tramadol).